Delfi Diagnostics Raises $100M in Series A Financing
Baltimore City-based Delfi Diagnostics Inc. cancer treatment center has raised $100M in Series A funding. The company plans to use the funding to expand its team of cancer researchers and machine learning experts to validate its novel next-generation liquid biopsy technology through multiple prospective clinical studies. The new technology platform is designed to detect and identify specific cancers in at-risk individuals. The funding round was led by multiple lenders and advised by T. Rowe Price Associates, Inc. Via